Zoetis Inc.ZTS

NYSEHealthcarePharmaceutical Preparations
Price (close)
$70.27
Market cap
$29.0B
P/E
11.1x
Revenue (TTM)
$9.5B
Net income
$2.6B
Dividend yield
2.97%
1-year total return
-49.3%
Net margin
27.5%
Revenue growth
1.5%
Debt / equity
2.87x

What Zoetis Inc. does.

Zoetis Inc. is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. We have a diversified business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical and animal health diagnostics. With a legacy of nearly 75 years, we continue to pioneer ways to predict, prevent, detect, and treat animal illness, supporting those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers.

We were incorporated in Delaware in July 2012 and prior to that the company was a business unit of Pfizer Inc. (Pfizer). The address of our principal executive offices is 10 Sylvan Way, Parsippany, New Jersey 07054. Unless the context requires otherwise, references to “Zoetis,” “the company,” “we,” “us” or “our” in this Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (2025 Annual Report) refer to Zoetis Inc., a Delaware corporation, and its subsidiaries. In addition, unless the context requires otherwise, references to “Pfizer” in this 2025 Annual Report refer to Pfizer Inc., a Delaware corporation, and its subsidiaries.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$6.7B$7.8B$8.1B$8.5B$9.3B$9.5B
Net income$1.6B$2.0B$2.1B$2.3B$2.5B$2.7B
Free cash flow$1.7B$1.7B$1.3B$1.6B$2.3B$2.3B

More on ZTS.

Figures from Zoetis Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.